MetaCap

Tectonic Therapeutic (TECX) vs Tevogen (TVGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Tectonic Therapeutic (TECX) has outperformed Tevogen (TVGN) over the past year, gaining 8.1% versus a loss of 73.8%. Tectonic Therapeutic is the larger company by market cap ($405.3 million vs $405.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

TECX+8.08%TVGN-73.84%
+107%+8%-92%
Nov 21, 20251 yearNov 20, 2026
TECX-18.51%TVGN-98.81%
+123%+7%-110%
Jan 3, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

TECX versus TVGN key metrics
MetricTECXTVGN
Share price$20.73$5.90
Market cap$405.26M$405.20M
1-day change-1.47%-6.35%
YTD return-0.62%-64.35%
1-year return+8.08%-73.84%
5-year return-57.66%—
EPS (TTM)$-4.63$-7.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-74.15M$-26.28M
52-week high$39.53$24.90
52-week low$16.77$3.64
Distance from 52-week high-47.56%-76.31%
Analyst consensusstrong_buy—
Avg. price target upside+242.50%—
Average volume212.16K7.94K
Shares outstanding19.55M68.68M
Employees6018
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TECX has outperformed TVGN by 81.9 percentage points over the past year.

About Tectonic Therapeutic

TECX stock →

Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees

About Tevogen

TVGN stock →

Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees

TECX vs TVGN FAQ

Which is bigger, Tectonic Therapeutic or Tevogen?

Tectonic Therapeutic (TECX) is larger, with a market capitalization of $405.26M compared with $405.20M for Tevogen (TVGN).

Which stock has performed better over the past year, TECX or TVGN?

TECX returned +8.08% over the past 12 months, compared with -73.84% for TVGN (price return, excluding dividends). Past performance does not predict future results.

Are Tectonic Therapeutic and Tevogen in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons